Adamis pharmaceuticals resubmits zimhi new drug application to fda for the treatment of opioid overdose

San diego, may 17, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the new drug application (nda) was resubmitted to the u.s. food and drug administration (fda) for zimhi™, a naloxone injection product candidate intended for the treatment of opioid overdose.
ADMP Ratings Summary
ADMP Quant Ranking